Loading...
•
Nov 30, 2024
Walgreens Q1 2025 Earnings Report
Walgreens reported Q1 2025 results, showing sales increase but a loss per share, with adjusted EPS impacted by lower U.S. retail sales and prior year gains, offset by cost savings and U.S. Healthcare growth; maintained full year adjusted EPS guidance.
Key Takeaways
Walgreens Boots Alliance reported a 7.5% increase in sales to $39.5 billion for the first quarter of fiscal year 2025. However, the company experienced a loss per share of $0.31, although adjusted EPS was $0.51. The company is maintaining its fiscal year 2025 adjusted EPS guidance of $1.40 to $1.80.
First quarter sales increased 7.5% year-over-year to $39.5 billion.
Loss per share was $0.31, including costs related to the Footprint Optimization Program.
Adjusted EPS was $0.51, driven by lower U.S. retail sales and prior year sale-leaseback gains, partly offset by cost savings and growth in U.S. Healthcare.
Fiscal 2025 adjusted EPS guidance maintained at $1.40 to $1.80.
Walgreens
Walgreens
Walgreens Revenue by Segment
Revenue by Segment
U.S. Pharmacy Revenue
CapyFin.comInternational Revenue
CapyFin.comU.S. Healthcare Revenue
CapyFin.com Forward Guidance
Walgreens is maintaining its fiscal year 2025 adjusted EPS guidance of $1.40 to $1.80.
Positive Outlook
- Growth in U.S. Healthcare
- Growth in International
- Disciplined execution against 2025 priorities
- Optimizing footprint
- Controlling operating costs
Challenges Ahead
- Decline in U.S. Retail Pharmacy
- Higher adjusted effective tax rate
- Lower contributions from sale-leaseback
- Lower Cencora earnings
- Turnaround will take time
Revenue & Expenses
Visualization of income flow from segment revenue to net income